NO311258B1 - Ribozym for in-vitro spalting av polyribonukleotid med en termodynamisk stabil lökke - Google Patents

Ribozym for in-vitro spalting av polyribonukleotid med en termodynamisk stabil lökke Download PDF

Info

Publication number: NO311258B1
Authority: NO; Norway
Prior art keywords: nucleotide; polyribonucleotide; cytosine; adenine; guanine
Prior art date: 1992-07-02

Application number

NO19945103A

Other languages

English (en)

Norwegian (no)

Other versions

NO945103L (no

NO945103D0 (no

Inventor

Eiko Otsuka

Makoto Koizumi

Original Assignee

Sankyo Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-02

Filing date

1994-12-30

Publication date

2001-11-05

1994-12-30 Application filed by Sankyo Co filed Critical Sankyo Co

1994-12-30 Publication of NO945103D0 publication Critical patent/NO945103D0/no

1995-03-02 Publication of NO945103L publication Critical patent/NO945103L/no

2001-11-05 Publication of NO311258B1 publication Critical patent/NO311258B1/no

Links

108091033319 polynucleotide Proteins 0.000 title claims abstract description 143
102000040430 polynucleotide Human genes 0.000 title claims abstract description 143
238000003776 cleavage reaction Methods 0.000 title claims description 67
230000007017 scission Effects 0.000 title claims description 45
238000000338 in vitro Methods 0.000 title claims description 10
108091092562 ribozyme Proteins 0.000 title abstract description 51
108090000994 Catalytic RNA Proteins 0.000 title abstract description 25
102000053642 Catalytic RNA Human genes 0.000 title abstract description 23
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 90
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 75
GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 72
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 66
238000000034 method Methods 0.000 claims description 45
239000002773 nucleotide Substances 0.000 claims description 42
125000003729 nucleotide group Chemical group 0.000 claims description 42
230000000295 complement effect Effects 0.000 claims description 28
239000013598 vector Substances 0.000 claims description 25
229940035893 uracil Drugs 0.000 claims description 2
230000000694 effects Effects 0.000 abstract description 14
241000282414 Homo sapiens Species 0.000 abstract description 5
229940124321 AIDS medicine Drugs 0.000 abstract 1
230000003327 cancerostatic effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 78
239000000243 solution Substances 0.000 description 44
108091032973 (ribonucleotides)n+m Proteins 0.000 description 40
108020004414 DNA Proteins 0.000 description 29
239000000758 substrate Substances 0.000 description 29
238000006243 chemical reaction Methods 0.000 description 26
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 20
238000004255 ion exchange chromatography Methods 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
108090000623 proteins and genes Proteins 0.000 description 15
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 14
239000002585 base Substances 0.000 description 14
239000013604 expression vector Substances 0.000 description 14
239000002904 solvent Substances 0.000 description 14
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 14
239000000203 mixture Substances 0.000 description 13
108700042226 ras Genes Proteins 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
241000588724 Escherichia coli Species 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
241000725303 Human immunodeficiency virus Species 0.000 description 12
239000012634 fragment Substances 0.000 description 12
230000014759 maintenance of location Effects 0.000 description 12
238000004007 reversed phase HPLC Methods 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
239000000872 buffer Substances 0.000 description 10
238000010438 heat treatment Methods 0.000 description 10
108020004999 messenger RNA Proteins 0.000 description 10
-1 dimethoxytrityl group Chemical group 0.000 description 9
102000039446 nucleic acids Human genes 0.000 description 9
108020004707 nucleic acids Proteins 0.000 description 9
150000007523 nucleic acids Chemical class 0.000 description 9
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
108091034117 Oligonucleotide Proteins 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
235000011114 ammonium hydroxide Nutrition 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
239000008223 sterile water Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
VKIGAWAEXPTIOL-UHFFFAOYSA-N 2-hydroxyhexanenitrile Chemical compound CCCCC(O)C#N VKIGAWAEXPTIOL-UHFFFAOYSA-N 0.000 description 7
238000010828 elution Methods 0.000 description 7
229910001629 magnesium chloride Inorganic materials 0.000 description 7
108020004705 Codon Proteins 0.000 description 6
238000010276 construction Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000002609 medium Substances 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
101150040459 RAS gene Proteins 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
239000005289 controlled pore glass Substances 0.000 description 5
230000029087 digestion Effects 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
241000196324 Embryophyta Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
235000010724 Wisteria floribunda Nutrition 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
238000010586 diagram Methods 0.000 description 4
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
108090001052 hairpin ribozyme Proteins 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 4
230000010076 replication Effects 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 4
239000003643 water by type Substances 0.000 description 4
102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
244000063299 Bacillus subtilis Species 0.000 description 3
235000014469 Bacillus subtilis Nutrition 0.000 description 3
102000012410 DNA Ligases Human genes 0.000 description 3
108010061982 DNA Ligases Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
108020005543 Satellite RNA Proteins 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
239000011575 calcium Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
238000012869 ethanol precipitation Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000002372 labelling Methods 0.000 description 3
239000011259 mixed solution Substances 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
239000011148 porous material Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
230000009466 transformation Effects 0.000 description 3
KBDDIZRDKLGWGW-UHFFFAOYSA-N 3-[4-(3-aminopropylamino)butylamino]propylazanium;chloride Chemical compound [Cl-].NCCCNCCCCNCCC[NH3+] KBDDIZRDKLGWGW-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000269333 Caudata Species 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
244000061176 Nicotiana tabacum Species 0.000 description 2
235000002637 Nicotiana tabacum Nutrition 0.000 description 2
108020005067 RNA Splice Sites Proteins 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
108020004487 Satellite DNA Proteins 0.000 description 2
241000726445 Viroids Species 0.000 description 2
241000700605 Viruses Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000000246 agarose gel electrophoresis Methods 0.000 description 2
238000000137 annealing Methods 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
238000012761 co-transfection Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
125000002652 ribonucleotide group Chemical group 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
108020004465 16S ribosomal RNA Proteins 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000744472 Cinna Species 0.000 description 1
102100025840 Coiled-coil domain-containing protein 86 Human genes 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
241001131785 Escherichia coli HB101 Species 0.000 description 1
241001646716 Escherichia coli K-12 Species 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
241000701533 Escherichia virus T4 Species 0.000 description 1
108090001102 Hammerhead ribozyme Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
101000932708 Homo sapiens Coiled-coil domain-containing protein 86 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241001045988 Neogene Species 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000008153 Peptide Elongation Factor Tu Human genes 0.000 description 1
108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
244000025272 Persea americana Species 0.000 description 1
235000008673 Persea americana Nutrition 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
206010064127 Solar lentigo Diseases 0.000 description 1
101150056072 TUFB gene Proteins 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000008272 agar Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
108090000637 alpha-Amylases Proteins 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000010187 selection method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
101150099542 tuf gene Proteins 0.000 description 1
101150071165 tuf1 gene Proteins 0.000 description 1
101150010742 tuf2 gene Proteins 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin

Landscapes

Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO19945103A 1992-07-02 1994-12-30 Ribozym for in-vitro spalting av polyribonukleotid med en termodynamisk stabil lökke NO311258B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP17570692		1992-07-02
JP23691692		1992-09-04
PCT/JP1993/000907 WO1994001549A1 (fr)	1992-07-02	1993-07-02	Ribozyme bouclee en epingle a cheveux

Publications (3)

Publication Number	Publication Date
NO945103D0 NO945103D0 (no)	1994-12-30
NO945103L NO945103L (no)	1995-03-02
NO311258B1 true NO311258B1 (no)	2001-11-05

Family

ID=26496887

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19945103A NO311258B1 (no)	1992-07-02	1994-12-30	Ribozym for in-vitro spalting av polyribonukleotid med en termodynamisk stabil lökke

Country Status (8)

Country	Link
US (1)	US5631115A (de)
EP (1)	EP0653488B1 (de)
AT (1)	ATE236975T1 (de)
AU (1)	AU672018B2 (de)
CA (1)	CA2139411A1 (de)
DE (1)	DE69332856D1 (de)
NO (1)	NO311258B1 (de)
WO (1)	WO1994001549A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19532651A1 (de) *	1995-09-05	1997-03-06	Aloysius Dr Dickgreber	Mittel zur therapeutischen Anwendung bei HIV-Infektionen
US5888767A (en) *	1996-11-27	1999-03-30	The Johns Hopkins University School Of Medicine	Method of using a conditionally replicating viral vector to express a gene
US5885806A (en) *	1995-11-28	1999-03-23	The Johns Hopkins University School Of Medicine	Methods to prepare conditionally replicating viral vectors
US6274369B1 (en) *	1996-02-02	2001-08-14	Invitrogen Corporation	Method capable of increasing competency of bacterial cell transformation
US8568766B2 (en)	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
AU9684601A (en)	2000-10-12	2002-04-22	Univ Rochester	Compositions that inhibit proliferation of cancer cells
US7811992B2 (en)	2002-02-06	2010-10-12	Stasys Technologies, Inc.	Anti-infarction molecules
EP1534729A2 (de) *	2002-02-26	2005-06-01	University of Utah Research Foundation	Mit bluthochdruck und virusknospung assoziierte nedd4l-varianten
US20040005546A1 (en) *	2002-02-28	2004-01-08	Oncolytics Biotech Inc.	Use of ribozymes in the detection of adventitious agents
CA2374388C (en)	2002-02-28	2005-07-12	Matthew C. Coffey	The use of ribozymes in the detection of adventitious agents
EP2116604A1 (de)	2002-08-05	2009-11-11	University of Rochester	Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon
US8512701B2 (en)	2002-11-15	2013-08-20	Morehouse School Of Medicine	Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US9233120B2 (en)	2002-11-15	2016-01-12	Jyant Technologies	Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8658377B2 (en)	2002-11-15	2014-02-25	Morehouse School Of Medicine	Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
WO2004050674A2 (en) *	2002-12-04	2004-06-17	Algos Therapeutics, Inc.	Methods and materials for modulating trpm2
WO2006083937A2 (en)	2005-02-02	2006-08-10	The Uab Research Foundation	Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
EP3312196B1 (de)	2005-03-23	2019-07-17	Genmab A/S	Antikörper gegen cd38 zur behandlung von multiplem myelom
US7476733B2 (en)	2005-03-25	2009-01-13	The United States Of America As Represented By The Department Of Health And Human Services	Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
FR2887259B1 (fr) *	2005-06-21	2007-09-14	Agronomique Inst Nat Rech	CONSTRUCTION D'ADNc D'ALPHAVIRUS DE SALMONIDES
EP1934244A2 (de) *	2005-10-06	2008-06-25	Emthrax LLC	Verfahren und zusammensetzungen in verbindung mit milzbrandsporen-glycoproteinen als impfstoffe
US8093369B2 (en) *	2005-10-11	2012-01-10	Ben Gurion University Of The Negev Research And Development Authority Ltd.	Compositions for silencing the expression of VDAC1 and uses thereof
US8080534B2 (en)	2005-10-14	2011-12-20	Phigenix, Inc	Targeting PAX2 for the treatment of breast cancer
EP2395076A1 (de)	2005-10-14	2011-12-14	MUSC Foundation For Research Development	Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
EP3034083B1 (de)	2006-09-21	2020-12-09	University of Rochester	Antisense-oligonukleotide zur behandlung von myotoner dystrophie
EP2104516B1 (de)	2006-11-01	2015-01-07	University of Rochester	Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
CA2667971C (en)	2006-11-01	2017-04-18	Gary Weisinger	Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
CN101600451A (zh)	2006-12-11	2009-12-09	犹他大学研究基金会	用于治疗病理性血管生成和血管通透性的组合物和方法
EP2195331B1 (de)	2007-08-28	2013-11-20	Uab Research Foundation	Synthetische, apolipoprotein e nachahmende polypeptide und anwendungsverfahren
US8557767B2 (en)	2007-08-28	2013-10-15	Uab Research Foundation	Synthetic apolipoprotein E mimicking polypeptides and methods of use
CA2706317C (en) *	2007-12-03	2017-06-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Doc1 compositions and methods for treating cancer
US20090233993A1 (en) *	2008-03-06	2009-09-17	Burnham Institute For Medical Research	Compositions and methods for inhibiting gsk3 activity and uses thereof
WO2009137686A1 (en)	2008-05-08	2009-11-12	University Of Utah Research Foundation	Sensory receptors for chronic fatigue and pain and uses thereof
US20120070443A1 (en)	2008-12-02	2012-03-22	University Of Utah Research Foundation	Pde1 as a target therapeutic in heart disease
US20110060000A1 (en)	2009-09-10	2011-03-10	Maurizio Grimaldi	Acridine analogs in the treatment of gliomas
US20110207789A1 (en)	2010-02-19	2011-08-25	Ye Fang	Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
EP2986317A4 (de)	2013-04-15	2016-10-05	Yeda Res & Dev	Hemmung von rip-kinasen zur behandlung lysosomaler speicherkrankheiten
CA2954475C (en)	2014-07-31	2023-05-16	Uab Research Foundation	Apoe mimetic peptides and higher potency to clear plasma cholesterol
US10723794B2 (en)	2015-03-18	2020-07-28	University Of South Carolina	Anti-CcL8 antibodies and uses thereof
AU2017306422A1 (en)	2016-08-03	2019-01-31	H. Lee Moffitt Cancer Center And Research Institute, Inc.	TLR9 targeted therapeutics
WO2019051355A1 (en)	2017-09-08	2019-03-14	Ohio State Innovation Foundation	NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS
IL267614A (en)	2019-06-24	2019-09-26	Lotem Michal	Nucleic acids to modulate SLAMF6 isoforms
US12492245B2 (en)	2021-09-21	2025-12-09	University Of South Carolina	Anti-CCL8 antibodies and treatment of lung injury by CCL8 inhibition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU632993B2 (en) *	1987-12-15	1993-01-21	Gene Shears Pty. Limited	Ribozymes
CA1340323C (en) *	1988-09-20	1999-01-19	Arnold E. Hampel	Rna catalyst for cleaving specific rna sequences

1993
- 1993-07-02 US US08/367,175 patent/US5631115A/en not_active Expired - Fee Related
- 1993-07-02 WO PCT/JP1993/000907 patent/WO1994001549A1/ja not_active Ceased
- 1993-07-02 EP EP93914943A patent/EP0653488B1/de not_active Expired - Lifetime
- 1993-07-02 AT AT93914943T patent/ATE236975T1/de not_active IP Right Cessation
- 1993-07-02 AU AU45130/93A patent/AU672018B2/en not_active Ceased
- 1993-07-02 CA CA002139411A patent/CA2139411A1/en not_active Abandoned
- 1993-07-02 DE DE69332856T patent/DE69332856D1/de not_active Expired - Lifetime
1994
- 1994-12-30 NO NO19945103A patent/NO311258B1/no unknown

Also Published As

Publication number	Publication date
NO945103L (no)	1995-03-02
EP0653488A4 (de)	1997-01-15
EP0653488B1 (de)	2003-04-09
AU672018B2 (en)	1996-09-19
ATE236975T1 (de)	2003-04-15
EP0653488A1 (de)	1995-05-17
CA2139411A1 (en)	1994-01-20
US5631115A (en)	1997-05-20
DE69332856D1 (de)	2003-05-15
AU4513093A (en)	1994-01-31
WO1994001549A1 (fr)	1994-01-20
NO945103D0 (no)	1994-12-30

Publication	Publication Date	Title
EP0653488B1 (de)	2003-04-09	Haarnadelförmiges ribozym
Navaratnam et al.	1993	Apolipoprotein B mRNA editing is associated with UV crosslinking of proteins to the editing site.
Wind et al.	2000	Transcription elongation factor SII
Dubin et al.	1995	Inverted repeats are necessary for circularization of the mouse testis Sry transcript
Datta et al.	1991	Genetic evidence for base pairing between U2 and U6 snRNA in mammalian mRNA splicing
McBurney et al.	1991	The mouse Pgk-1 gene promoter contains an upstream activator sequence
JP3131222B2 (ja)	2001-01-31	ギャップを有する２′修飾オリゴヌクレオチド
AU2015364282B2 (en)	2021-04-15	CRISPR-based compositions and methods of use
Sheets et al.	1989	Two phases in the addition of a poly (A) tail.
CA2563388C (en)	2013-01-08	Microrna and methods for inhibiting same
AU2020399673A1 (en)	2022-07-28	Antisense guide RNA with added functional region for editing target RNA
Hosking et al.	1995	Trans-activation and DNA-binding properties of the transcription factor, Sox-18
Vanhée-Brossollet et al.	1998	Do natural antisense transcripts make sense in eukaryotes?
WO1995014030A1 (en)	1995-05-26	Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
JPH03502638A (ja)	1991-06-20	リボザイム
WO2002046449A2 (en)	2002-06-13	Selection of catalytic nucleic acids targeted to infectious agents
Zhang et al.	2004	Multiple functions of nuclear DNA helicase II (RNA helicase A) in nucleic acid metabolism
WO2011160052A2 (en)	2011-12-22	Methods and compositions for sequence specific rna endonucleases
WO2008087641A2 (en)	2008-07-24	H19 silencing nucleic acid agents for treating rheumatoid arthritis
Abe et al.	1998	Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligonucleotides
Hill et al.	1999	Homologous human and murine antisense oligonucleotides targeting Stat6: functional effects on germline C ɛ transcript
US20060079471A1 (en)	2006-04-13	Snornai-small nucleolar rna degradation by rna interference in trypanosomatids
EP2071030A2 (de)	2009-06-17	Oligoribonukleotid- und Peptidnukleinsäure zur Hemmung der Aktivität des Hepatitis-C-Virus
Tachas et al.	2006	A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice
Kim et al.	1988	Functional analysis of the interaction of a tissue-specific factor with an upstream enhancer element of the rat prolactin gene